CLINICAL TRIALS PROFILE FOR NUEDEXTA
✉ Email this page to a colleague
All Clinical Trials for NUEDEXTA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01630811 ↗ | Nuedexta for the Treatment of Adults With Autism | Completed | Sutter Health | Phase 2 | 2012-01-24 | Primary: Demonstrate reduced frequency and intensity of maladaptive behaviors as measured by the Aberrant Behavior Checklist (ABC) Irritability subscale in subjects given Nuedexta 8 weeks over subjects given placebo. Secondary: Demonstrate a trend towards reduced aggressive behavior as measured by Overt Aggression Scale (OAS). |
NCT01799941 ↗ | Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) | Completed | OptumInsight Life Sciences | Phase 4 | 2013-02-01 | The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with prevalent conditions such as dementia, stroke, and traumatic brain injury (TBI)over a 12 week period. |
NCT01799941 ↗ | Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) | Completed | Avanir Pharmaceuticals | Phase 4 | 2013-02-01 | The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with prevalent conditions such as dementia, stroke, and traumatic brain injury (TBI)over a 12 week period. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NUEDEXTA
Condition Name
Clinical Trial Locations for NUEDEXTA
Trials by Country
Clinical Trial Progress for NUEDEXTA
Clinical Trial Phase
Clinical Trial Sponsors for NUEDEXTA
Sponsor Name